Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2010 Jul;7(3):232–240. doi: 10.1016/j.nurt.2010.05.011

Improving the prediction of response to therapy in autism

Stephen Bent 1,2,3,✉, Robert L Hendren 1
PMCID: PMC5084226  PMID: 20643375

Summary

Autism is a heterogeneous disorder involving complex mechanisms and systems occurring at diverse times. Because an individual child with autism may have only a subset of all possible abnormalities at a specific time, it may be challenging to identify beneficial effects of an intervention in double-blind, randomized, controlled trials, which compare the mean responses to treatments. Beneficial effects in a small subset of children may be obscured by the lack of effect in the majority. We review the evidence for several potential model systems of biochemical abnormalities that may contribute to the etiology of autism, we describe potential biomarkers or treatment targets for each of these abnormalities, and we provide illustrative treatment trials using this methodology. Potential model systems include immune over and under reactivity, inflammation, oxidative stress, free fatty acid metabolism, mitochondrial dysfunction, and excitotoxicity. Including potential biomarkers and targeted treatments in clinical trials for autism provides a potential method for limiting the heterogeneity of enrolled subjects, which may improve the power of studies to identify beneficial effects of treatments while also improving the understanding of the disease.

Key Words: Autism, randomized controlled trials, biomarker, complementary, alternative therapy

References

  • 1.Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators. Centers for Disease Control and Prevention (CDC) Prevalence of autism spectrum disorders — Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ. 2009;58:1–20. [PubMed] [Google Scholar]
  • 2.Educating Children with Autism. Washington, DC: National Academy Press, 2001.
  • 3.Ospina MB, Krebs Seida J, Clark B, et al. Behavioural and developmental interventions for autism spectrum disorder: a clinical systematic review. PloS One. 2008;3:e3755–e3755. doi: 10.1371/journal.pone.0003755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314–321. doi: 10.1056/NEJMoa013171. [DOI] [PubMed] [Google Scholar]
  • 5.Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:e634–e641. doi: 10.1542/peds.2003-0264-F. [DOI] [PubMed] [Google Scholar]
  • 6.Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48:1110–1119. doi: 10.1097/CHI.0b013e3181b76658. [DOI] [PubMed] [Google Scholar]
  • 7.Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124:1533–1540. doi: 10.1542/peds.2008-3782. [DOI] [PubMed] [Google Scholar]
  • 8.King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009;66:583–590. doi: 10.1001/archgenpsychiatry.2009.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.ACTN Trial: Study of fluoxetine in autism (SOFIA). http://www. autismspeaks.org/science/programs/ctn/index.php#fluoxetine_study. Accessed April 21, 2009.
  • 10.Harrington JW, Rosen L, Garnecho A, Patrick PA. Parental perceptions and use of complementary and alternative medicine practices for children with autistic spectrum disorders in private practice. J Dev Behav Pediatr. 2006;27:S156–S161. doi: 10.1097/00004703-200604002-00014. [DOI] [PubMed] [Google Scholar]
  • 11.Heuer L, Ashwood P, Schauer J, et al. Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res. 2008;1:275–283. doi: 10.1002/aur.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Enstrom AM, Onore CE, Van de Water JA, Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun xxxx;24:64–71. [DOI] [PMC free article] [PubMed]
  • 13.Enstrom AM, Lit L, Onore CE, et al. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain, behavior, and immunity. 2009;23:124–133. doi: 10.1016/j.bbi.2008.08.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Enstrom AM, Van de Water JA, Ashwood P. Autoimmunity in autism. Curr Opin Investig Drugs. 2009;10:463–473. [PMC free article] [PubMed] [Google Scholar]
  • 15.Ashwood P, Wills S, Van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol. 2006;80:1–15. doi: 10.1189/jlb.1205707. [DOI] [PubMed] [Google Scholar]
  • 16.Chez MG, Dowling T, Patel PB, Khanna P, Kominsky M. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol. 2007;36:361–365. doi: 10.1016/j.pediatrneurol.2007.01.012. [DOI] [PubMed] [Google Scholar]
  • 17.Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. International review of psychiatry (Abingdon, England) 2005;17:485–495. doi: 10.1080/02646830500381930. [DOI] [PubMed] [Google Scholar]
  • 18.Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57:67–81. doi: 10.1002/ana.20315. [DOI] [PubMed] [Google Scholar]
  • 19.Zimmerman AW, Jyonouchi H, Comi AM, et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol. 2005;33:195–201. doi: 10.1016/j.pediatrneurol.2005.03.014. [DOI] [PubMed] [Google Scholar]
  • 20.Ashwood P, Wakefield AJ. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol. 2006;173:126–134. doi: 10.1016/j.jneuroim.2005.12.007. [DOI] [PubMed] [Google Scholar]
  • 21.Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin — the antioxidant proteins. Life Sci. 2004;75:2539–2549. doi: 10.1016/j.lfs.2004.04.038. [DOI] [PubMed] [Google Scholar]
  • 22.James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004;80:1611–1617. doi: 10.1093/ajcn/80.6.1611. [DOI] [PubMed] [Google Scholar]
  • 23.Yorbik O, Sayal A, Akay C, Akbiyik DI, Sohmen T. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids. 2002;67:341–343. doi: 10.1054/plef.2002.0439. [DOI] [PubMed] [Google Scholar]
  • 24.Mostafa GA, El-Hadidi ES, Hewedi DH, Abdou MM. Oxidative stress in Egyptian children with autism: relation to autoimmunity. J Neuroimmunol. 2010;219:114–118. doi: 10.1016/j.jneuroim.2009.12.003. [DOI] [PubMed] [Google Scholar]
  • 25.James SJ, Rose S, Melnyk S, et al. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. Faseb J. 2009;23:2374–2383. doi: 10.1096/fj.08-128926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bell JG, Miller D, Macdonald DJ, et al. The fatty acid composition of erythrocyte and plasma polar lipids in children with autism, developmental delay or typically developing controls and the effect of fish oil intake. Br J Nutr. 2010;103:1160–1167. doi: 10.1017/S0007114509992881. [DOI] [PubMed] [Google Scholar]
  • 27.Bell JG, MacKinlay EE, Dick JR, MacDonald DJ, Boyle RM, Glen AC. Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukot Essent Fatty Acids. 2004;71:201–204. doi: 10.1016/j.plefa.2004.03.008. [DOI] [PubMed] [Google Scholar]
  • 28.Meguid NA, Atta HM, Gouda AS, Khalil RO. Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem. 2008;41:1044–1048. doi: 10.1016/j.clinbiochem.2008.05.013. [DOI] [PubMed] [Google Scholar]
  • 29.Vancassel S, Durand G, Barthelemy C, et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids. 2001;65:1–7. doi: 10.1054/plef.2001.0281. [DOI] [PubMed] [Google Scholar]
  • 30.Bu B, Ashwood P, Harvey D, King IB, Water JVd, Jin LW. Fatty acid compositions of red blood cell phospholipids in children with autism. Prostaglandins Leukot Essent Fatty Acids. 2006;74:215–221. doi: 10.1016/j.plefa.2006.02.001. [DOI] [PubMed] [Google Scholar]
  • 31.Zecavati N, Spence SJ. Neurometabolic disorders and dysfunction in autism spectrum disorders. Curr Neurol Neurosci Rep. 2009;9:129–136. doi: 10.1007/s11910-009-0021-x. [DOI] [PubMed] [Google Scholar]
  • 32.Oliveira G, Diogo L, Grazina M, et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol. 2005;47:185–189. doi: 10.1017/S0012162205000332. [DOI] [PubMed] [Google Scholar]
  • 33.Weissman JR, Kelley RI, Bauman ML, et al. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PloS One. 2008;3:e3815–e3815. doi: 10.1371/journal.pone.0003815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma amino acid levels in children with autism and their families. J Autism Dev Disord. 2003;33:93–97. doi: 10.1023/A:1022238706604. [DOI] [PubMed] [Google Scholar]
  • 35.Niederhofer H. Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. J Clin Psychopharmacol. 2007;27:317–318. doi: 10.1097/01.jcp.0000270082.30500.69. [DOI] [PubMed] [Google Scholar]
  • 36.Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry. 2002;52:805–810. doi: 10.1016/S0006-3223(02)01430-0. [DOI] [PubMed] [Google Scholar]
  • 37.Polleux F, Lauder JM. Toward a developmental neurobiology of autism. BMC Complement Altem Med. 2004;10:303–317. doi: 10.1002/mrdd.20044. [DOI] [PubMed] [Google Scholar]
  • 38.Bertoglio K, James JS, Deprey L, Brule N, Hendren RL. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. BMC Complement Altem Med. 2010;16:1–6. doi: 10.1089/acm.2009.0177. [DOI] [PubMed] [Google Scholar]
  • 39.Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–537. doi: 10.1126/science.286.5439.531. [DOI] [PubMed] [Google Scholar]
  • 40.Alizadeh AA, Staudt LM. Genomic-scale gene expression profiling of normal and malignant immune cells. Curr Opin Immunol. 2000;12:219–225. doi: 10.1016/S0952-7915(99)00078-3. [DOI] [PubMed] [Google Scholar]
  • 41.Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344:539–548. doi: 10.1056/NEJM200102223440801. [DOI] [PubMed] [Google Scholar]
  • 42.Staudt LM. Gene expression physiology and pathophysiology of the immune system. Trends Immunol. 2001;22:35–40. doi: 10.1016/S1471-4906(00)01792-0. [DOI] [PubMed] [Google Scholar]
  • 43.Simons JW. Genomic medicines for oncology: early lessons. J Med Assoc Ga. Winter-Spring. 2003;92:35–38. [PubMed] [Google Scholar]
  • 44.Chin KV, Alabanza L, Fujii K, et al. Application of expression genomics for predicting treatment response in cancer. Ann N Y Acad Sci. 2005;1058:186–195. doi: 10.1196/annals.1359.025. [DOI] [PubMed] [Google Scholar]
  • 45.Carroll WL, Bhojwani D, Min DJ, Moskowitz N, Raetz EA. Childhood acute lymphoblastic leukemia in the age of genomics. Pediatr Blood Cancer. 2006;46:570–578. doi: 10.1002/pbc.20722. [DOI] [PubMed] [Google Scholar]
  • 46.Green VA, Pituch KA, Itchon J, Choi A, O’Reilly M, Sigafoos J. Internet survey of treatments used by parents of children with autism. Res Dev Disabil. 2006;27:70–84. doi: 10.1016/j.ridd.2004.12.002. [DOI] [PubMed] [Google Scholar]
  • 47.Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry. 2007;61:551–553. doi: 10.1016/j.biopsych.2006.05.007. [DOI] [PubMed] [Google Scholar]
  • 48.Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nute. 2002;21:495–505. doi: 10.1080/07315724.2002.10719248. [DOI] [PubMed] [Google Scholar]
  • 49.Young G, Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev. 2005;45:1–28. doi: 10.1051/rnd:2005001. [DOI] [PubMed] [Google Scholar]
  • 50.Rossignol DA, Rossignol LW. Hyperbaric oxygen therapy may improve symptoms in autistic children. Med Hypotheses. 2006;67:216–228. doi: 10.1016/j.mehy.2006.02.009. [DOI] [PubMed] [Google Scholar]
  • 51.Rossignol DA. Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism. Med Hypotheses. 2007;68:1208–1227. doi: 10.1016/j.mehy.2006.09.064. [DOI] [PubMed] [Google Scholar]
  • 52.Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr. 2009;9:21–21. doi: 10.1186/1471-2431-9-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Granpeesheh D, Tarbox J, Dixon DR, Wilke AE, Allen MS, Bradstreet JJ. Randomized trial of hyperbaric oxygen therapy for children with autism. Res Autism Spectr Disord. 2010;4:268–275. doi: 10.1016/j.rasd.2009.09.014. [DOI] [Google Scholar]
  • 54.Tomchek SD, Dunn W. Sensory processing in children with and without autism: a comparative study using the short sensory profile. Am J Occup Ther. 2007;61:190–200. doi: 10.5014/ajot.61.2.190. [DOI] [PubMed] [Google Scholar]
  • 55.Roberts TP, Schmidt GL, Egeth M, et al. Electrophysiological signatures: magnetoencephalographic studies of the neural correlates of language impairment in autism spectrum disorders. Int J Psychophysiol. 2008;68:149–160. doi: 10.1016/j.ijpsycho.2008.01.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Wilson TW, Rojas DC, Reite ML, Teale PD, Rogers SJ. Children and adolescents with autism exhibit reduced MEG steady-state gamma responses. Biol Psychiatry. 2007;62:192–197. doi: 10.1016/j.biopsych.2006.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Farzin F, Rivera SM, Hessl D. Brief report: visual processing of faces in individuals with fragile X syndrome: an eye tracking study. J Autism Dev Disord. 2009;39:946–952. doi: 10.1007/s10803-009-0744-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Aman MG, Novotny S, Samango-Sprouse C, et al. Outcome measures for clinical drug trials in autism. CNS Spectrums. 2004;9:36–47. doi: 10.1017/s1092852900008348. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES